- Pathologic complete response following FOLFIRINOX and olaparib treatment for hepatic metastasized pancreatic ductal adenocarcinoma with a germline BRCA mutation.
- Okada K, Uemura K, Okamoto W, Sumiyoshi T, Shintakuya R, Otsuka H, Serikawa M, Ishii Y, Arihiro K, Takahashi S.
- Clin J Gastroenterol. 2022 Dec 27. doi: 10.1007/s12328-022-01741-2. Epub ahead of print.
- PMID: 36574187
- PubMed abstract
- Source abstract
- Case report
- CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
- Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, Anglesio MS, Ataseven B, Barlow E, Beckmann MW, Berger J, Bisinotto C, Bösmüller H, Boros J, Brand AH, Brooks-Wilson A, Brucker SY, Carney ME, Casablanca Y, Cazorla-Jiménez A, Cohen PA, Conrads TP, Cook LS, Coulson P, Courtney-Brooks M, Cramer DW, Crowe P, Cunningham JM, Cybulski C, Darcy KM, El-Bahrawy MA, Elishaev E, Erber R, Farrell R, Fereday S, Fischer A, García MJ, Gayther SA, Gentry-Maharaj A, Gilks CB; AOCS Group, Grube M, Harnett PR, Harrington SP, Harter P, Hartmann A, Hecht JL, Heikaus S, Hein A, Heitz F, Hendley J, Hernandez BY, Polo SH, Heublein S, Hirasawa A, Høgdall E, Høgdall CK, Horlings HM, Huntsman DG, Huzarski T, Jewell A, Jimenez-Linan M, Jones ME, Kaufmann SH, Kennedy CJ, Khabele D, Kommoss FKF, Kruitwagen RFPM, Lambrechts D, Le ND, Lener M, Lester J, Leung Y, Linder A, Loverix L, Lubiński J, Madan R, Maxwell GL, Modugno F, Neuhausen SL, Olawaiye A, Olbrecht S, Orsulic S, Palacios J, Pearce CL, Pike MC, Quinn CM, Mohan GR, Rodríguez-Antona C, Ruebner M, Ryan A, Salfinger SG, Sasamoto N, Schildkraut JM, Schoemaker MJ, Shah M, Sharma R, Shvetsov YB, Singh N, Sonke GS, Steele L, Stewart CJR, Sundfeldt K, Swerdlow AJ, Talhouk A, Tan A, Taylor SE, Terry KL, Tołoczko A, Traficante N, Van de Vijver KK, van der Aa MA, Van Gorp T, Van Nieuwenhuysen E, van-Wagensveld L, Vergote I, Vierkant RA, Wang C, Wilkens LR, Winham SJ, Wu AH, Benitez J, Berchuck A, Candido Dos Reis FJ, DeFazio A, Fasching PA, Goode EL, Goodman MT, Gronwald J, Karlan BY, Kommoss S, Menon U, Sinn HP, Staebler A, Brenton JD, Bowtell DD, Pharoah PDP, Ramus SJ, Köbel M.
- Cancer. 2022 Dec 26. doi: 10.1002/cncr.34582. Epub ahead of print.
- PMID: 36572991
- PubMed abstract
- Source abstract
- Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel.
- Mahtani R, Niyazov A, Arondekar B, Lewis K, Rider A, Massey L, Lux MP.
- BMC Cancer. 2022 Dec 22;22(1):1343. doi: 10.1186/s12885-022-10325-9.
- PMID: 36550413
- PubMed abstract
- Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes.
- Mihajlovich Tsyganov MM, Ibragimova MK, Garbukov EY, Bragina OD, Karchevskaya AA, Usynin EA, Litvyakov NV.
- Int J Mol Sci. 2022 Dec 22;24(1):207. doi: 10.3390/ijms24010207.
- LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer.
- [No author given]
- Merck.com . News releases. 2022 Dec 21.
- Press release
- Free Full Text
•• Press release: Lynparza in combination with abiraterone approved in the EU as 1st-line treatment for patients with metastatic castration-resistant prostate cancer. (AstraZeneca. Media.)
- Deep learning identifies morphological patterns of homologous recombination deficiency in luminal breast cancers from whole slide images.
- Lazard T, Bataillon G, Naylor P, Popova T, Bidard FC, Stoppa-Lyonnet D, Stern MH, Decencière E, Walter T, Vincent-Salomon A..
- Cell Rep Med. 2022 Dec 20;3(12):100872. doi: 10.1016/j.xcrm.2022.100872. Epub 2022 Dec 13.
- PMID: 36516847
- PubMed abstract
•• Commentary:
HRD-related morphology discovery in breast cancer by controlling for confounding factors.
- PMID: 36543118
- PubMed abstract
- Source abstract
- Codelivery of adavosertib and olaparib by tumor-targeting nanoparticles for augmented efficacy and reduced toxicity.
- Wang W, Xiong Y, Hu X, Lu F, Qin T, Zhang L, Guo E, Yang B, Fu Y, Hu D, Fan J, Qin X, Liu C, Xiao R, Chen G, Li Z, Sun C.
- Acta Biomater. 2022 Dec 19:S1742-7061(22)00824-8. doi: 10.1016/j.actbio.2022.12.021. Epub ahead of print.
- PMID: 36549633
- PubMed abstract
- Review
- Free Full Text
- 53BP1: Keeping It under Control, Even at a Distance from DNA Damage.
- Rass E, Willaume S, Bertrand P.
- Genes (Basel). 2022 Dec 16;13(12):2390. doi: 10.3390/genes13122390.
- PMID: 36553657
- PubMed abstract
- Review
- Free PMC article
- Free Full Text
- Update on US regulatory priority review of Lynparza in combination with abiraterone in metastatic castration-resistant prostate cancer.
- Kemp A.
- AstraZeneca. Media. Press Releases. 2022 Dec 15.
- Press release
- Free Full Text
- BRCA1/2 Reversion Mutations in Patients Treated with Poly ADP-Ribose Polymerase (PARP) Inhibitors or Platinum Agents.
- Darabi S, Braxton DR, Xiu J, Carneiro BA, Swensen J, Antonarakis ES, Liu SV, McKay RR, Spetzler D, El-Deiry WS, Demeure MJ.
- Medicina (Kaunas). 2022 Dec 10;58(12):1818. doi: 10.3390/medicina58121818.
- PMID: 36557020
- PubMed abstract